Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial

AIMS: To assess the dose‐related effects of sotagliflozin, a novel dual inhibitor of sodium‐glucose co‐transporters‐1 and ‐2, in type 1 diabetes (T1D). MATERIALS AND METHODS: In this 12‐week, multicentre, randomized, double‐blind, placebo‐controlled dose‐ranging trial, adults with T1D were randomize...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, Claire, Wason, Suman, Banks, Phillip, Sawhney, Sangeeta, Chang, Anna, Danne, Thomas, Gesty‐Palmer, Diane, Kushner, Jake A., McGuire, Darren K., Mikell, Frank, O'Neill, Mark, Peters, Anne L., Strumph, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851757/
https://www.ncbi.nlm.nih.gov/pubmed/31264767
http://dx.doi.org/10.1111/dom.13825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851757/
https://www.ncbi.nlm.nih.gov/pubmed/31264767
http://dx.doi.org/10.1111/dom.13825

Ejemplares similares